STAT+: Biotech Doubles Financing in Quest to Silence Genes Behind Neurological Diseases

Why It Matters

The capital boost accelerates Aerska’s preclinical pipeline, potentially delivering the first scalable gene‑silencing treatments that can cross the blood‑brain barrier, a long‑standing hurdle in neurology. Success could reshape the CNS therapeutic market and attract further investment in precision RNA medicines.

Key Takeaways

• Aerska raised $39 million in new financing.
• Funding follows initial round just four months earlier.
• Technology uses iron‑mimicking antibody to cross blood‑brain barrier.
• siRNA cargo silences disease‑causing genes in the brain.
• Founders include Alnylam veteran Stuart Milstein.

Pulse Analysis

The brain’s protective blood‑brain barrier (BBB) has long limited the delivery of large‑molecule therapeutics, forcing biotech firms to seek clever workarounds. Aerska, a Dublin‑London startup, tackles this obstacle with a proprietary “brain shuttle” that disguises siRNA payloads as iron‑bound antibodies, exploiting the brain’s natural demand for iron. By hitching gene‑silencing RNA to an iron‑mimetic carrier, the platform can ferry molecules across the endothelial tight junctions that normally block them, opening a pathway for treating neurodegenerative and neuro‑developmental disorders that were previously undruggable.

The recent $39 million financing round, led by a mix of venture capital and strategic investors, underscores growing confidence in RNA‑based neuromodulation. Coming just four months after Aerska’s seed round, the back‑to‑back capital influx provides runway to advance preclinical programs targeting pathogenic genes implicated in Huntington’s disease, ALS, and certain forms of epilepsy. The involvement of industry veteran Stuart Milstein, formerly of Alnylam, adds credibility and signals potential partnerships with established RNA therapeutics players seeking to expand into central nervous system indications.

From an investment perspective, Aerska’s model aligns with a broader shift toward precision medicines that address root genetic causes rather than symptoms. If the brain shuttle proves scalable, it could unlock a new class of CNS drugs, attracting further funding and possibly reshaping the competitive landscape for biotech firms focused on gene silencing. Stakeholders—from pharma executives to patient advocacy groups—will watch closely as Aerska moves toward IND‑enabling studies, a milestone that could validate the iron‑shuttle concept and accelerate market entry.